Impact of levothyroxine in women with positive thyroid antibodies on pregnancy outcomes: a systematic review and meta-analysis of randomised controlled trials

Lorraine Lau,1 Jamie L Benham,1,2 Patricia Lemieux,1 Jennifer Yamamoto,1,3,4,5 Lois E Donovan1,5

ABSTRACT

Objective To evaluate the effect of levothyroxine therapy on pregnancy outcomes compared with placebo or no treatment in women without overt hypothyroidism with presence of thyroid peroxidase antibodies (TPOAb) and/or thyroglobulin antibodies (TgAb).

Design Systematic review and meta-analysis of randomised controlled trials

Study eligibility criteria Prespecified criteria for inclusion were: randomised trials of levothyroxine versus control (placebo or no treatment) among women with positive TPOAb or TgAb who were pregnant or considering conception.

Data sources Ovid MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched from 1980 to 5 November 2020.

Outcome measures Prespecified data elements were extracted and where appropriate, meta-analyses were conducted. Main outcomes include pregnancy achieved, miscarriage, preterm delivery and live birth.

Risk of bias assessment Cochrane Risk of Bias Tool for Quality Assessment of Randomised Controlled Trials.

Results From 3023 citations, 79 citations were identified for full-text review. Of these, six trials (total of 2263 women) were included for qualitative and quantitative analyses. Risk of bias was deemed low for only one trial. There was no significant difference in the relative risk (RR) of pregnancy achieved (RR 1.03; 95% CI 0.93 to 1.13), miscarriage (RR 0.93; 95% CI 0.76 to 1.14), preterm delivery (RR 0.66; 95% CI 0.39 to 1.10) or live births (RR 1.01; 95% CI 0.89 to 1.16) in thyroid autoimmune women treated with levothyroxine compared with controls. Sensitivity analyses of preterm birth identified study quality and timing of levothyroxine initiation as sources of heterogeneity.

Conclusions Among pregnant women or women planning conception, with thyroid autoimmunity, there is a lack of evidence of benefit for levothyroxine use (moderate to high Grading of Recommendations, Assessment, Development and Evaluations). Recommendations to use levothyroxine in this setting need to be reconsidered.

PROSPERO registration number CRD42019130459.

INTRODUCTION

As thyroid function is frequently screened during the early gestational period, identification of thyroid immunity, defined by the presence of thyroid peroxidase antibodies (TPOAb) and/or thyroglobulin antibodies (TgAb), is relatively common in pregnant women. The prevalence of TPOAb positivity in the first trimester ranges from 5% to 15% in unselected pregnant women.1 The prevalence of thyroid autoimmunity is even higher in women with a history of recurrent pregnancy loss, reported as 23%–31%.3,4

The association between thyroid autoimmunity and poor pregnancy outcomes, specifically miscarriage and preterm birth, has been well described.5,6 However, the mechanism linking thyroid autoimmunity with increased risk of miscarriage and preterm birth in women without overt hypothyroidism is unclear. Two competing mechanistic theories propose that (1) thyroid autoantibodies are a marker of a hostile immune environment or (2) thyroid autoantibodies act as a surrogate biomarker of impaired thyroid hormone reserves, despite normal thyroid function tests.7 If the latter theory is true, one could postulate that supplementation with...
levothyroxine may improve thyroid hormone levels and prevent negative pregnancy outcomes.

Whether or not levothyroxine therapy, either prior to or during pregnancy, improves pregnancy outcomes in women with thyroid autoimmunity is controversial. The 2017 American Thyroid Association (ATA) pregnancy guidelines strongly recommends levothyroxine for women with thyroid autoimmunity and a thyroid stimulating hormone (TSH) above the pregnancy-specific reference range. These guidelines recommend a consideration of levothyroxine in thyroid autoimmune women with TSH above 2.5 mIU/L and among euthyroid women with positive TPOAb and a history of pregnancy loss.

The evidence evaluating levothyroxine treatment in pregnant women with thyroid autoantibodies is conflicting as evidenced by three recent systematic reviews and meta-analyses. The discrepant results may be attributed to the inclusion of small observational studies and the lack of inclusion of a recently published large multicentre trial. Additionally, the limitations of observational studies must be considered. Observational studies identify associations, but do not provide the highest level of evidence for determining causation or therapeutic efficacy. Randomised controlled trials are considered the gold standard to evaluate therapeutic efficacy. Therefore, we performed a systematic review and meta-analysis to evaluate all randomised controlled trials of levothyroxine therapy in women with thyroid autoimmunity who were pregnant or planning pregnancy.

METHODS

Protocol and registration

A systematic review and meta-analysis was performed as outlined in the registered protocol (PROSPERO CRD42019130459), and is reported in accordance with the Preferred Reporting Items for Reviews and Meta-Analyses.

Data sources and search strategy

The following databases were searched in duplicate on 17 April 2019 (and updated on 5 November 2020) from 1980: Ovid MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials. ClinicalTrials.gov was searched for active trials. The search strategy was developed in consultation with a medical librarian and used a combination of keywords related to hypothyroidism or thyroid autoimmunity and pregnancy (online supplemental S1). The search was conducted using an adapted version of the Cochrane search filter for randomised controlled trials where possible and was limited to human studies.

Study selection

Studies that met all the following criteria were included in this review: (1) pregnant women or women contemplating pregnancy (including patients seeking assisted reproductive technologies), with positive TPOAb or TgAb, euthyroid or with subclinical hypothyroidism (by any prespecified study definition); (2) randomised to levothyroxine vs control (placebo or no treatment); (3) reported pregnancy outcomes; (4) reported in either English or French; (5) published from 1980 to 5 November 2020. The publication year 1980 was specifically chosen to coincide with the availability of more sensitive TSH assays.

Study selection was completed in two separate stages by two independent reviewers (PL and LED or LL and JLB). First, duplicates were removed, and titles and abstracts were screened for eligibility (by PL and LED). Second, full citations deemed eligible at the title and abstract stage were retrieved and reviewed for eligibility in a full-text format (by LL and JLB). Inclusion criteria was applied to select eligible articles and reasons for exclusion were recorded. Agreement was recorded at each stage and reported as a kappa statistic. All disagreements between reviewers were solved by consensus, and, if needed, by discussion with a third independent reviewer (LED). Prior to each selection step, a pilot calibration was conducted by the respective reviewers to review inclusion criteria.

The reference list of included articles was searched for the addition of further relevant studies.

Data collection process

Relevant study information was extracted by two independent reviewers (LL and JB) using standardised data extraction forms in Microsoft Excel (V.16.16.18, Microsoft Corporation, Redmon, Washington, USA). Extracted data elements included: study design, country, participant inclusion and exclusion criteria, TPOAb and TgAb results, definition of TPOAb and TgAb positivity, TPOAb and TgAb assays used, thyroid stimulating hormone (TSH) and thyroxine (T4) assays used and normal ranges, baseline serum concentrations of TSH and T4, iodine status of the country, levothyroxine dosing, achieved TSH and T4 after treatment, gestational timing of levothyroxine initiation, duration of treatment, details of the intervention, quality of the methods, inclusion of patients with subclinical hypothyroidism and definition of subclinical hypothyroidism, patient baseline characteristics, number of patients included in each group, pregnancy outcomes and their definitions.

Quality assessment

Cochrane Risk of Bias Tool for Quality Assessment of Randomised Controlled Trials was used to assess study quality and evaluate the risk of bias by two independent reviewers (LL and JLB). This tool assesses seven methodologic domains and these components enable classification of randomised trials as ‘low risk of bias’, ‘high risk of bias’ or ‘unclear risk of bias’.

Study outcomes

The following pregnancy outcomes were prespecified and included: pregnancy by trial definition, miscarriage, preterm delivery, live birth, birth weight, large for gestational age, small for gestational age, gestational age at...
RESULTS

The search results are summarised in figure 1. Among the 3023 citations reviewed for title and abstract, 79 citations were identified for full-text review. Six randomised controlled trials (total of 2263 women) met all eligibility criteria and were included in the qualitative and quantitative analyses. There was a substantial level of agreement for both the title and abstract review (κ=0.64) and for the full-text review (κ=0.70).

Trial characteristics

Trial characteristics are summarised in table 1. Three trials initiated levothyroxine therapy prior to conception, whereas three trials initiated therapy in the first trimester. Two trials compared levothyroxine to placebo, and the other four trials compared with no treatment. Reproductive technologies were used in three trials, with one trial not specifying details with this regard. All trials included women with positive TPOAb with only one trial including TPO or Tg antibodies. The TSH normal reference ranges and definition of TPO positivity were prespecified in each trial and are summarised in table 1.

Patient characteristics

Baseline participant characteristics are summarised in table 1 and online supplemental S2. Mean maternal age ranged from 26 years to 32 years. Mean reported body mass index ranged from 22.7 kg/m² to 26.5 kg/m². Baseline TSH values varied according to assay specific reference ranges. Baseline-free T4 values were comparable in the three trials that reported this information (online supplemental S2). There was insufficient information to assess the outcome of childhood neurodevelopment.

Risk of bias assessment

Risk of bias assessment is presented in figure 2. Only one trial was considered ‘low risk’ of bias in all seven domains. Four trials were assessed at ‘low risk’ for selection bias. Two trials were ‘unclear risk of bias’ in allocation concealment. In four trials comparing levothyroxine to no treatment, the assessors were not blinded to patient randomisation and thus these trials were considered to be ‘high risk’ for performance bias. Published trial protocols were located for only two trials. Thus, only these two trials were assessed as ‘low risk’ for reporting bias.

Pregnancy outcomes

There were sufficient data for meta-analyses of four pregnancy outcomes, as summarised in figure 3. These outcomes include pregnancy achieved, miscarriage, preterm delivery and live births. Pregnancy achieved was reported in three trials (n=1026) that initiated levothyroxine preconception. There was no significant difference in pregnancy achieved in thyroid autoimmune women treated levothyroxine compared with control (RR 1.03, 95% CI 0.93 to 1.13; I²=0%). GRADE was rated as high quality for this outcome (table 2).

Miscarriage was reported in all six trials (n=1427) and was defined as pregnancy loss at less than 20 weeks, less
<table>
<thead>
<tr>
<th>Study Author (year)/ Country</th>
<th>N</th>
<th>Intervention levothyroxine</th>
<th>Control</th>
<th>Use of assisted reproduction technologies (% of participants)</th>
<th>Inclusion of subclinical hypothyroidism</th>
<th>TSH (Normal range; mIU/L)</th>
<th>Definition of TPOAb positivity (IU/mL)</th>
<th>Mean GA of LT4 initiation (weeks)</th>
<th>Baseline TSH (mIU/L) (median, *mean)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhillon-Smith et al (2019)/ UK</td>
<td>952</td>
<td>Initiated preconception</td>
<td>Placebo</td>
<td>Yes (45)</td>
<td>No</td>
<td>0.44–3.63</td>
<td>&gt;99% concordance with UK NEQAS IIA</td>
<td>Preconception</td>
<td>2.1</td>
</tr>
<tr>
<td>Nazarpour et al (2017)/ Iran</td>
<td>131</td>
<td>Initiated 4–8 days following first prenatal visit</td>
<td>No treatment</td>
<td>Unclear</td>
<td>Yes</td>
<td>0.1–2.5</td>
<td>&gt;50</td>
<td>11.4±4.2</td>
<td>11.4±4.2</td>
</tr>
<tr>
<td>Negro et al (2005)/ Italy</td>
<td>72</td>
<td>Initiated 1 month before assisted reproduction technologies</td>
<td>No treatment</td>
<td>Yes (100)</td>
<td>Yes</td>
<td>0.27–3.2</td>
<td>&gt;100</td>
<td>Preconception</td>
<td>Preconception</td>
</tr>
<tr>
<td>Negro et al (2006)/ Italy</td>
<td>115</td>
<td>Initiated at first endocrinological visit (2-7d after first obstetrics visit)</td>
<td>Placebo</td>
<td>No</td>
<td>No</td>
<td>0.27–4.2</td>
<td>&gt;100</td>
<td>10.4±3.1</td>
<td>10.3±3.1</td>
</tr>
<tr>
<td>Negro et al (2016)/ Italy</td>
<td>393</td>
<td>Initiated in first trimester prior to 12 weeks</td>
<td>No treatment</td>
<td>No</td>
<td>No</td>
<td>0.5–2.5</td>
<td>&gt;16</td>
<td>7.1±1.2</td>
<td>7.0±1.2</td>
</tr>
<tr>
<td>Wang et al (2017)/ China</td>
<td>600</td>
<td>Initiated 2–4 weeks prior to controlled ovarian hyperstimulation</td>
<td>No treatment</td>
<td>Yes (100)</td>
<td>No</td>
<td>0.45–4.78</td>
<td>60</td>
<td>Preconception</td>
<td>Preconception</td>
</tr>
</tbody>
</table>

FT4, free thyroxine; GA, gestational age; LT4, levothyroxine; NEQAS IIA, National External Quality Assurance Service IIA; TPOAb, thyroid peroxidase antibody; TSH, thyroid stimulating hormone.
than 24 weeks, less than 28 weeks (early miscarriage defined as first 12 weeks, late miscarriage defined as between 13 and 28 weeks),14 or not clearly defined.10–12 There was no significant difference in the RR of miscarriage in TPOAb-positive pregnant women treated with levothyroxine compared with control (RR 0.93, 95% CI 0.76 to 1.14; I²=0%). Inclusion of trials8 11 14 that initiated levothyroxine only preconception revealed no significant difference compared with control (RR 0.91, 95% CI 0.72 to 1.15; I²=0%). GRADE was rated as high quality for this outcome (table 2).

Preterm delivery was reported in five trials (n=1354).8–10 12 14 Preterm delivery was defined as live birth prior to 34 weeks8 or 37 weeks.9 10 12 14 There was no significant difference in the RR of preterm delivery in thyroid autoimmune pregnant women treated with levothyroxine compared with control (RR 0.91, 95% CI 0.72 to 1.15; I²=0%). GRADE was rated as high quality for this outcome (table 2).

Sensitivity analyses
A sensitivity analysis was performed to explore the heterogeneity of our meta-analysis for preterm delivery. Results are summarised in online supplemental S4.

TSH levels at baseline were subdivided into TSH ≤2.5 mIU/mL8 10 12 and TSH >2.5 mIU/mL.9 14 The RR of preterm delivery in pregnant women with baseline TSH ≤2.5 mIU/mL was 0.64 (95% CI 0.36 to 1.14; I²=32%) compared with an RR of 0.62 (95% CI 0.17 to 2.33; I²=80%) in pregnant women with baseline TSH >2.5 mIU/mL.

Timing of levothyroxine initiation was stratified into preconception8 14 and in pregnancy.9 10 12 The RR of preterm delivery in women initiated on levothyroxine preconception was 1.10 (95% CI 0.69 to 1.75; I²=0%) compared an RR of 0.46 (95% CI 0.28 to 0.75; I²=2%) in women initiated on levothyroxine in the first trimester.

The RR of preterm delivery in women using assisted reproductive technologies (ART)8 14 was 1.10 (95% CI 0.69 to 1.75; I²=0%) compared with an RR of 0.51 (95% CI 0.26 to 1.02; I²=27%) in women that did not use ART.10 12

Sensitivity analyses were also performed to explore the impact of fixed8 14 and adjusted levothyroxine9 10 12 14 doses on miscarriage rates (online supplemental S5). The RR of fixed levothyroxine dose was 0.89 (95% CI 0.66 to 1.20; I²=12%) compared with adjusted levothyroxine dose of 0.95 (95% CI 0.68 to 1.33; I²=0%).

Study quality was defined as high if there was low risk of bias across all seven domains of the Cochrane
A Pregnancy achieved

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Placebo/No treatment</th>
<th>Levothyroxine</th>
<th>Relative Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhillon-Smith, 2019</td>
<td>274</td>
<td>470</td>
<td>296</td>
</tr>
<tr>
<td>Negro 2005</td>
<td>21</td>
<td>43</td>
<td>24</td>
</tr>
<tr>
<td>Wang 2017</td>
<td>113</td>
<td>300</td>
<td>107</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>813</td>
<td>1373</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

B Miscarriage

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Levothyroxine</th>
<th>Placebo/No treatment</th>
<th>Relative Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhillon-Smith, 2019</td>
<td>75</td>
<td>266</td>
<td>81</td>
</tr>
<tr>
<td>Nazarpour 2017</td>
<td>2</td>
<td>24</td>
<td>6</td>
</tr>
<tr>
<td>Negro 2006</td>
<td>2</td>
<td>24</td>
<td>6</td>
</tr>
<tr>
<td>Negro 2016</td>
<td>33</td>
<td>198</td>
<td>29</td>
</tr>
<tr>
<td>Wang 2017</td>
<td>11</td>
<td>107</td>
<td>12</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>708</td>
<td>2064</td>
<td>719</td>
</tr>
</tbody>
</table>

C Preterm delivery

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Levothyroxine</th>
<th>Placebo/No treatment</th>
<th>Relative Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhillon-Smith, 2019</td>
<td>10</td>
<td>266</td>
<td>10</td>
</tr>
<tr>
<td>Nazarpour 2017</td>
<td>4</td>
<td>56</td>
<td>14</td>
</tr>
<tr>
<td>Negro 2005</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Negro 2006</td>
<td>4</td>
<td>57</td>
<td>13</td>
</tr>
<tr>
<td>Negro 2016</td>
<td>14</td>
<td>198</td>
<td>21</td>
</tr>
<tr>
<td>Wang 2017</td>
<td>21</td>
<td>95</td>
<td>19</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>672</td>
<td>1552</td>
<td>682</td>
</tr>
</tbody>
</table>

D Live births

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Placebo or No treatment</th>
<th>Levothyroxine</th>
<th>Relative Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhillon-Smith, 2019</td>
<td>178</td>
<td>470</td>
<td>176</td>
</tr>
<tr>
<td>Wang 2017</td>
<td>97</td>
<td>300</td>
<td>95</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>777</td>
<td>1777</td>
<td>777</td>
</tr>
</tbody>
</table>

Figure 3 Results of meta-analysis of effects of levothyroxine treatment on pregnancy and obstetrical outcomes. M-H, Mantel-Haenszel.

Collaboration’s tool. We were unable to perform a sensitivity analysis exploring the impact of risk of bias on preterm delivery, as only one trial met the definition for high quality per the Cochrane Collaboration tool.8 A funnel plot for preterm delivery is shown in online supplemental S6. On visual inspection, there was asymmetry indicating potential publication bias towards smaller studies reporting positive findings.

Table 2 Grading of Recommendations, Assessment, Development and Evaluations (GRADE) scoring of the quality of evidence for the main outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Pregnancy achieved</th>
<th>Miscarriage</th>
<th>Preterm delivery</th>
<th>Live births</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk of bias</td>
<td>Strong</td>
<td>Strong</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Imprecision</td>
<td>Strong</td>
<td>Strong</td>
<td>Moderate</td>
<td>Strong</td>
</tr>
<tr>
<td>Inconsistency</td>
<td>Strong</td>
<td>Strong</td>
<td>Weak</td>
<td>Strong</td>
</tr>
<tr>
<td>Indirectness</td>
<td>Strong</td>
<td>Strong</td>
<td>Strong</td>
<td>Strong</td>
</tr>
<tr>
<td>Publication bias</td>
<td>Strong</td>
<td>Strong</td>
<td>Weak</td>
<td>Strong</td>
</tr>
<tr>
<td>Overall GRADE</td>
<td>High quality</td>
<td>High quality</td>
<td>Moderate quality</td>
<td>High quality</td>
</tr>
</tbody>
</table>
DISCUSSION

This systematic review and meta-analysis of randomised controlled trials of levothyroxine therapy in women with thyroid autoimmunity without overt thyroid dysfunction demonstrates no evidence of benefit of levothyroxine therapy across prespecified pregnancy outcomes. Specifically, treatment with levothyroxine did not improve pregnancies achieved, miscarriage preterm delivery or live birth across a total of 2263 women, inclusive of those with a history of pregnancy loss and use of reproductive technologies. Furthermore, the availability of larger and better-quality trials since the publications of the ATA 2017 pregnancy recommendations signals the need to update these guidelines as they pertain to the treatment of thyroid autoimmune women.

Small randomised clinical trials initially demonstrated that levothyroxine therapy reduced miscarriage and/or preterm delivery in TPOAb-positive women compared with placebo or no treatment intervention. However, the unclear definition of miscarriage and preterm delivery among these early trials means that selective reporting of outcomes could have biased their reported findings. Subsequent large, multi-centre randomised controlled trials with clear prespecified outcome definitions have shown no impact of levothyroxine therapy on maternal or fetal outcomes compared with no levothyroxine treatment in pregnant women with subclinical hypothyroidism, isolated hypothyroxinaemia or positive TPOAbs. These intervention trials involved pregnant women or women seeking pregnancy, including individuals with a history of pregnancy loss.

A systematic review and meta-analysis of a large study population (n=47 045) of individual participant and population data demonstrated increased risk of preterm birth in TPOAb-positive women. In light of these findings, Cappola and Casey highlighted the need to address whether levothyroxine treatment decreases the risk of preterm birth among women with TPOAb. Three other systematic reviews and meta-analyses examined the effect of levothyroxine supplementation in pregnant women with thyroid autoimmunity. Unlike our review which only included randomised controlled trials, two of the other reviews included observational studies. The findings of our meta-analysis were consistent with the review by Sun et al., which showed no benefit of levothyroxine supplementation on their pregnancy outcomes. In contrast, Rao et al. demonstrated a beneficial effect of levothyroxine treatment on reducing pregnancy loss and preterm birth among pregnant women with subclinical hypothyroidism and/or thyroid autoimmunity. Several notable distinctions likely account for these discrepant results. First, the Dhillon-Smith et al. publication was not included in these reviews. Furthermore, both reviews by Rao et al. included a trial that strongly influenced their results but did not report outcome data in sufficient detail to be included in our systematic review. Our attempts to clarify the outcome data of this trial with the authors were left unresponded.

The findings of our study are consistent with the results of a recent systematic review and meta-analysis of randomised controlled trials of women with positive TPO antibodies. These authors also conclude that levothyroxine supplementation is not associated with improvement in pregnancy outcomes. This further emphasises the need to reconsider the current 2017 ATA guidelines on use of levothyroxine in euthyroid women with thyroid autoimmunity.

Most miscarriages occur early in pregnancy, prior to the first obstetrics appointment, thus initiation of levothyroxine prior to conception best addresses its impact on miscarriage rates. The pathophysiology underlying the association between thyroid autoimmunity in euthyroid pregnant women and miscarriage is still not completely understood. One hypothesis postulates that thyroid autoimmunity reflects inadequate thyroid reserves to accommodate for increased physiologic demands of pregnancy. It has been postulated that delayed initiation of levothyroxine in pregnancy may account for its failure to reduce miscarriage. Our meta-analysis found that initiation of levothyroxine preconception or in the first trimester did not impact miscarriage outcomes. This suggests that adequate thyroid reserve in women with thyroid autoimmunity does not account for the increased risk for miscarriage. A highly anticipated trial T4-LIFE that has not yet been published may further address the role of levothyroxine administration in women with TPOAb and recurrent miscarriage.

Sensitivity analyses based on timing of levothyroxine initiation demonstrated a reduction in preterm delivery when levothyroxine was initiated in the first trimester rather than preconception. However, this finding is likely attributed to the quality of the included studies since many of the trials that initiated levothyroxine in the first trimester were at high risk of bias and the funnel plot suggests publication bias. Furthermore, it appears biologically implausible that levothyroxine would be beneficial for thyroid autoimmune women when initiated during pregnancy but not when initiated preconception.

A limitation of this study is that only one of the six included trials met all criteria for low risk of bias. Meta-analyses of live births and neonatal outcomes such as gestational age at delivery and birth weight were limited as only two trials reported these outcomes. Furthermore, the sensitivity analysis is limited by the small number of studies included. Lastly, the funnel plot suggests publication bias towards smaller studies reporting positive findings. Interpretation of the funnel plot is limited by the small number of studies included in this meta-analysis. This study has many notable strengths. First, this study provides an updated summary of randomised controlled trials not included in previous systematic reviews and meta-analyses or available at the time of the ATA 2017 pregnancy guideline recommendations development. The systematic review and meta-analysis
provides moderate (GRADE) evidence for the preterm delivery and high (GRADE) evidence for the outcomes of pregnancy achieved, miscarriage and live birth to guide clinical decisions. Our systematic review and meta-analysis benefits from the use of rigorous standardised tools such as Cochrane Risk of Bias tool23a a prespecified analysis plan posted on Prospero, sensitivity analysis that address study quality and the assessment of publication bias.

CONCLUSION

In summary, data from six randomised controlled trials fail to demonstrate evidence of benefit from levothyroxine treatment for pregnancy outcomes in thyroid autoimmune women with normal thyroid function and subclinical hypothyroidism. In the absence of overt thyroid dysfunction, current trial evidence does not support the levothyroxine treatment of thyroid autoimmunity prevention or during the pregnancy. Given the lack of evidence of benefit of levothyroxine therapy, it is time to re-examine recommendations for screening TPOAb and treatment of women with thyroid autoimmunity preconception or in pregnancy.

Author affiliations
1Section of Endocrinology and Metabolism, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
2Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
3Department of Obstetrics and Gynecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
4Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
5Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Acknowledgements We thank Zahra Premji, PhD, MLIS (University of Calgary, Calgary, Alberta) for her expert advice on our search strategy.

Contributors PL and LED conceived the idea for this systematic review and meta-analysis, and conducted the literature search along with the initial title/abstract review. JY contributed her expertise in systematic review methodology to the design and conduct of this systematic review. LL and JLB conducted the full-text review, study selection, data extraction and statistical analyses. LL wrote the first draft of the manuscript. All authors contributed to critical review and approval of the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The authors adhered to the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines. Ethical committee approval was not required for this study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

REFERENCES

22 Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213–20.